Northwest Biotherapeutics (NWBO) Net Income towards Common Stockholders Growth (5y) (2015 - 2026)
Powered by 
Analysis
Northwest Biotherapeutics (NWBO) Net Income towards Common Stockholders Growth (5y) (2015 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | Northwest Biotherapeutics | 278.23 Mn | 277.63 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -33.03% |
| Mar 31, 2026 | 3.78% |
| Dec 31, 2025 | 14.92% |
| Sep 30, 2025 | 32.51% |
| Jun 30, 2025 | 22.78% |
| Mar 31, 2025 | -56.76% |
| Dec 31, 2024 | -45.98% |
| Sep 30, 2024 | -25.59% |
| Jun 30, 2024 | -143.50% |
| Mar 31, 2024 | 2.06% |
| Dec 31, 2023 | -20.44% |
| Sep 30, 2023 | -37.20% |
| Jun 30, 2023 | 9.54% |
| Mar 31, 2023 | 18.96% |
| Dec 31, 2022 | -0.02% |
| Sep 30, 2022 | -7.14% |
| Jun 30, 2022 | -23.68% |
| Mar 31, 2022 | -2.41% |
| Dec 31, 2021 | 50.90% |
| Sep 30, 2021 | 16.40% |